OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703, a Cytotoxic Monoclonal Antibody Targeting IL-7R, in Cancer Patients

NEXT STORY
Best Strategies for Co-creating Solutions with Patients
PREV STORY
Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ALGAE DYNAMICS CORP ANNOUNCES C$400,000 RESEARCH GRANT FROM MITACS TO SUPPORT CANNABIS RESEARCH WITH UNIVERSITY OF WESTERN ONTARIO

TORONTO, Nov. 16, 2017 (GLOBE NEWSWIRE) -- ALGAE DYNAMICS CORP (OTC: ADYNF) (the "Company"), ...

author_avatar
NASDAQ Market News

ZIOPHARM Reports Third Quarter 2016 Financial Results and Provides Update on Recent Activities

BOSTON, Nov. 09, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company ...

author_avatar
NASDAQ Market News

Yale Study Demonstrates Four-Fold Superiority of Academic Level Diagnostic Accuracy

NEW HAVEN, Conn., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ...

author_avatar
NASDAQ Market News